This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
KPV (10 mg Vial)
KPV (Lysine–Proline–Valine) is a C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH) studied for its potent anti-inflammatory properties without melanotropic side effects[1][2]. Research demonstrates KPV reduces pro-inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation[3].
Quick Reference
What is KPV?
Research overview based on the cited scientific literature.
• Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects[1][3].
• Storage: Lyophilized frozen at −20 °C (−4 °F) or below; reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality and stability.
• Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light[6][7].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days[7].
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid freeze–thaw cycles: Do not refreeze reconstituted peptide solutions; prepare aliquots if long-term storage is needed[6].
How is KPV studied?
KPV is the C-terminal tripeptide sequence (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH), retaining potent anti-inflammatory activity without the hormone’s melanotropic effects[1][2]. Preclinical studies demonstrate KPV reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF-κB) signaling and modulation of inflammatory mediator release[2]. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti-inflammatory effects observed in daily dosing protocols[4].
What does the research report about KPV?
Observations from preclinical and early-stage research.
• Anti-inflammatory activity: Reduces pro-inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation[3].
• Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability[4].
• Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation[5].
• Generally well tolerated: Occasional mild injection-site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
• No melanotropic effects: Unlike full α-MSH, KPV does not affect melanocyte activity or skin pigmentation[1].
Research Limitations / Risk Notes
KPV research remains primarily preclinical and early-stage. Research cited in the supplied source includes inflammatory bowel disease, colitis, systemic inflammation, wound-healing, and route-of-administration models[3][4][5]. KPV is a research peptide not approved by regulatory agencies for human therapeutic use.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.